MYMD PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.52 USD | +12.00% |
|
+0.80% | -67.53% |
| Apr. 09 | Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data | MT |
| Apr. 09 | Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell | MT |
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 13.17M |
|---|---|---|---|---|---|
| Net income 2022 | -15M | Net income 2023 | -4M | EV / Sales 2022 | - |
| Net cash position 2022 | 4.69M | Net cash position 2023 | 4.87M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-2.94
x | P/E ratio 2023 |
-1.46
x | Employees | 6 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.94% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +12.00% | ||
| 1 week | +0.80% | ||
| Current month | +5.44% | ||
| 1 month | -11.27% | ||
| 3 months | -55.08% | ||
| 6 months | -80.07% | ||
| Current year | -67.53% |
1 week
2.00
2.52
1 month
2.003.50
Current year
2.008.70
1 year
2.0070.50
3 years
2.00298.50
5 years
2.00298.50
10 years
2.00298.50
| Managers | Title | Age | Since |
|---|---|---|---|
Ian Rhodes
DFI | Director of Finance/CFO | 51 | 21-04-14 |
| President | 71 | 20-10-31 | |
Adam Kaplin
CTO | Chief Tech/Sci/R&D Officer | 57 | 20-12-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 58 | 17-08-07 | |
| President | 71 | 20-10-31 | |
Joshua Silverman
CHM | Chairman | 53 | 18-09-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 2.52 | +12.00% | 54,002 |
| 24-04-17 | 2.25 | +7.14% | 45,453 |
| 24-04-16 | 2.1 | -7.49% | 114,158 |
| 24-04-15 | 2.27 | -5.42% | 46,706 |
| 24-04-12 | 2.4 | -4.00% | 126,960 |
Delayed Quote Nasdaq, April 18, 2024 at 04:30 pm EDT
More quotes
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Companyâs MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Companyâs second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
| 1st Jan change | Capi. | |
|---|---|---|
| -67.53% | 5.44M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -2.33% | 21.66B | |
| -18.35% | 20.77B | |
| -8.38% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- MYMD Stock
